PMPaul S. Meltzer

Paul S. Meltzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul S. Meltzer has a total of 514 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TCF4 and CtBP1 Repress LEF1 to Maintain a TCF4-centric Transcriptional Program in Colon Cancer

    by Markus A. Brown, Sanam Yaghoubi, Juliane Kamlah, Wei-Dong Chen, Darawalee Zong, Sepehr Talebian Khorasani, Tianzuo Zhan, Michael Boutros, Jordi Camps, Paul Meltzer

    The canonical WNT signaling pathway guides cell growth throughout the human lifespan. In adults, WNT plays an essential role in tissue homeostasis by maintaining tissue stem cells. In the intestine, the WNT transcription factor, TCF4, is necessary for stem cell maintenance. Aberrant activation of WNT signaling is generally accepted as an initiating event in colon cancer, leading to constitutive TCF4 activity. To investigate the role of this key transcription factor in global gene regulation, we abrogated TCF4 expression in colon cancer cells. Loss of TCF4 function resulted in the over-expression of the WNT transcription factor, LEF1 . LEF1 was transcriptionally competent and over-compensated for TCF4 ( TCF7L2 ) silencing in a WNT reporter assay. TCF4 enlisted the transcriptional repressor CtBP1, and bound the LEF1 promoter, indicative of direct repression. TCF4 and LEF1 drove different transcriptional programs, with TCF4 favoring MYC and cell cycle progression, while LEF1 favored immune-related gene signatures. TCF4 was the primary regulator of MYC expression, yet also the mediator of LEF1 repression, suggestive of competition centered on TCF4 transcriptional output despite the β-catenin saturated colon cancer nucleus. We conclude that TCF4 has dual activator-repressor activity in colon cancer.

  • A complex mutational signature generated by cytarabine resistance

    by Dengchao Cao, Mianmian Yin, Ryan Bertoli, Zhenhua Zhang, Allyson Lu, Jack Zhu, Timour Baslan, Yang Jo Chung, Vijay Negi, Paul Meltzer, et al.

    T-cell acute lymphoblastic leukemia (T-ALL) patients generally respond well to chemotherapy, but T-ALL cells at relapse are typically resistant to chemotherapy. The specific mechanisms leading to chemoresistance are incompletely understood. We used Mcm2 hypomorph T-ALL cell lines, which are prone to copy number variant mutations, to identify acquired mutations that underlie chemoresistance. We found acquired copy number variants leading to resistance to a wide spectrum of chemotherapeutic agents and focused on cell lines that inactivated both Dck and Trp53, leading to cytarabine resistance and a unique mutational signature. This signature is characterized by C > T mutations in a GCG trinucleotide context, T > C in a GTC context, T > G in GTC and GTT contexts, and C > G in a GCC context. Ongoing cytarabine exposure is not required for this mutational signature. Further analyses revealed that the T > C in GTC context is associated with proliferation rate, while the C > G in GCC context is associated with Trp53 mutations. These findings provide new insight into the genetic evolution of chemoresistance, add to emerging evidence that chemotherapeutic agents can produce characteristic mutational signatures, and demonstrate that mutagenic effects of chemotherapy can be indirect, acting through selection of clones with distinct mutation profiles and a resultant mutator phenotype.

  • Open Access

    Supp_Fig_S1-S19 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development

    by Ryan M. Bertoli, Yang Jo Chung, Michael J. Difilippantonio, Anthony Wokasch, Madison R.B. Marasco, Haley Klimaszewski, Susannah Gammell, Yuelin J. Zhu, Robert L. Walker, Dengchao Cao, et al.

  • Open Access

    Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development

    by Ryan M. Bertoli, Yang Jo Chung, Michael J. Difilippantonio, Anthony Wokasch, Madison R.B. Marasco, Haley Klimaszewski, Susannah Gammell, Yuelin J. Zhu, Robert L. Walker, Dengchao Cao, et al.

  • Open Access

    Mitogen-Activated Protein Kinase and Chromosome Instability in the Initiation and Evolution of Medullary Thyroid Carcinoma 

    by Paolo Salerno, Yulong Li, Paul S. Meltzer, See Pdf

    We applied targeted next generation sequencing (NGS) to study the genomes of 245 medullary thyroid carcinomas (MTC). Hereditary (n=28) MTC was invariably due to germline RET mutations. In 98% of sporadic MTC, mutually exclusive clonal alterations in RET, HRAS, KRAS or BRAF oncogenes along the mitogen-activated protein kinase (MAPK) pathway were found. Novel kinase fusions (RET::MAP4 and MKRN1::BRAF) were functionally identified as new MTC drivers. Molecular cytogenetic analyses identified varying levels of copy number aberrations quantitated as copy number aberration burden (CNAB). High CNAB was a risk factor for MTC patients’ overall survival independently from other risk factors. The presence of secondary additional mutations was also associated with reduced survival. These data are consistent with a model in which MTC pathogenesis is initiated by MAPK followed by evolution due to chromosome instability (CIN), with high CNAB identified as a new clinicopathological factor for risk stratification.

  • Cancer-Associated DAXX Mutations Reveal a Critical Role for ATRX Localization in ALT Suppression

    by Sarah F. Clatterbuck Soper, Robert L. Walker, Marbin A. Pineda, Yuelin J. Zhu, James L. T. Dalgleish, Jasmine Wang, Paul S. Meltzer

    To maintain genome stability, proliferating cells must enact a program of telomere maintenance. While most tumors maintain telomeres using telomerase, a subset of tumors utilize a DNA-templated process termed alternative lengthening of telomeres or ALT. ALT is associated with mutations in the ATRX/DAXX/H3.3 histone chaperone complex, which is responsible for deposition of histone variant H3.3 at heterochromatic regions of the genome including telomeres. We wished to better understand the role DAXX plays in ALT suppression, and to determine which disease-associated DAXX mutations are unable to suppress ALT. To answer this question, we leveraged the G292 cell line, in which ATRX is wild-type but DAXX has undergone a fusion event. Restoration of wild-type DAXX in G292 localizes ATRX and abrogates ALT. Using this model system, we tested the ability of disease-associated DAXX missense variants to suppress ALT. Missense mutations in the ATRX binding domain, the histone binding domain, and the C-terminal SUMO interaction motif reduce the ability of DAXX to suppress ALT. Unexpectedly, we find that mutations in the DAXX histone binding domain lead to failure of ATRX localization. We conclude that a key function of DAXX in ALT suppression is the localization of ATRX to nuclear foci.


  • Open Access

    Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

    by John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, et al.

    Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells

  • Open Access

    Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

    by John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, et al.

    Supplemental methods and figures

  • Open Access

    Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

    by John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, et al.

    Purpose:Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations are often resistant to cytotoxic chemotherapy, radiotherapy, and many targeted therapies. We evaluated guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in these patient populations.Patients and Methods:Phase II study of guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle) to assess clinical activity (according to RECISTv.1.1) across three strata of patients with dSDH GIST, pheochromocytoma/paraganglioma, or HLRCC-RCC. A Simon optimal two-stage design (target response rate 30% rule out 5%) was used. Biologic correlates (methylation and metabolites) from peripheral blood mononuclear cells (PBMC), serum, and urine were analyzed.Results:Nine patients (7 with dSDH GIST, 1 each with paraganglioma and HLRCC-RCC, 6 females and 3 males, age range 18–57 years) were enrolled. Two patients developed treatment-limiting neutropenia. No partial or complete responses were observed (range 1–17 cycles of therapy). Biologic activity assessed as global demethylation in PBMCs was observed. No clear changes in metabolite concentrations were observed.Conclusions:Guadecitabine was tolerated in patients with dSDH tumors with manageable toxicity. Although 4 of 9 patients had prolonged stable disease, there were no objective responses. Thus, guadecitabine did not meet the target of 30% response rate across dSDH tumors at this dose, although signs of biologic activity were noted.

  • JoVE Video Dataset

    by Sarah F. Clatterbuck Soper, Paul S. Meltzer

    Visualizing telomeres using fluorescence in situ hybridization (TelFISH) has long been an essential tool in telomere biology experiments. Combining TelFISH with immunofluorescence (IF) is also a well-established method (IF-TelFISH), for example, in identifying telomere dysfunction-induced foci, where telomeres co-localize with 53BP1. More recently, native telomere FISH (nTelFISH) has become an important tool for assaying Alternative Lengthening of Telomeres, a telomere maintenance mechanism used in some tumor cells. Expressing fluorescent proteins is also an essential tool in cell biology, allowing visualization of proteins and structures that may remain undetectable by other methods. Because FISH buffers denature proteins, performing the assay in cells with an expressed fluorescent protein (FP) results in loss of FP signal. A method for integrating IF and telomere FISH in cells with an expressed fluorescent protein that preserves the FP signal even after FISH is described here. Alternatives are provided for denaturing and native telomere FISH in combination with several IF and FP scenarios. Taken together, this protocol offers a flexible framework for exploring telomere biology in both normal and tumor cells.